|Videos|October 28, 2022

“Power in the Hands of Patients”: Creating an Accessible Monkeypox Diagnostic

Author(s)Nina Cosdon

It’s not enough to have accurate infectious disease diagnostics, they must be accessible to the patients most affected.

In May 2022, cases of monkeypox virus began to be reported in nonendemic countries. “Frankly, this presentation of monkeypox is arguably a novel presentation,” said Paritosh Prasad, MD. “The current outbreak is one that’s different than how it has presented in the past.”

Prasad is an infectious disease doctor and intensive care doctor at the University of Rochester and the director of global health for VisualDx. “In the past several months, we’ve been working very actively on monkeypox identification and disseminating knowledge about it,” he said.

VisualDx has been working to develop image analysis of monkeypox to aid in its diagnosis. At the recent IDWeek conference, Prasad and his team were actively meeting with potential collaborators to source images and improve the accuracy of this technology.

The necessity of this work, Prasad says, is in the stigma surrounding monkeypox. All infectious diseases are marred by stigma, and it means that the populations who are disproportionately affected by monkeypox are perceived negatively.

“When you have the confluence of a disease process that creates fear, that creates stigma…diagnosis becomes incredibly difficult,” said Prasad, explaining this is why it is vital to create tools “that not only aid in that diagnosis, but tools that could even be placed in the hands of patients.”

It’s not enough to have reliable diagnostics, Prasad argues, if these are inaccessible for patients. “The population that’s currently facing the majority of the burden of disease is classically the population that doesn’t have the access to care.”


Related to this article

Ebola Outbreak Tops 10,000 Cases as CDC Cites Spread to Kenya, Nigeria
The CDC reports the Bundibugyo virus outbreak in the Democratic Republic of the Congo (DRC) is now the second-largest Ebola outbreak on record. As of October 28, the agency counted 10,305 total confirmed cases and 4,996 total confirmed deaths. The overall risk to the American public and travelers remains low, and no cases tied to this outbreak have been confirmed in the US.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.